Skip to content

Clinical trials

Urinary Bladder Neoplasms trials in Denmark

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Urinary Bladder Neoplasms Country / region: Denmark Clear all

69 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20012
20053
20061
20072
20081
20091
20111
20123
20131
20143
20157
20165
20173
20184
20199
20209
20213
20222
20232
20241
20254
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed41
Unknown status13
Recruiting6
Active, not recruiting3
Terminated3
Enrolling by invitation2
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Rigshospitalet, Denmark10
Jørgen Bjerggaard Jensen9
University of Aarhus6
Aarhus University Hospital5
Merck Sharp & Dohme LLC4
European Organisation for Research and Treatment of Cancer - EORTC3
Dr Anders Ullén2
Eli Lilly and Company2
Herlev Hospital2
Seagen Inc.2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Urinary Bladder Neoplasms69
Carcinoma, Transitional Cell8
Prostatic Neoplasms7
Breast Neoplasms6
Esophageal Neoplasms6
Ovarian Neoplasms6
Endometrial Neoplasms5
Lung Neoplasms5
Urethral Neoplasms5
Carcinoma, Non-Small-Cell Lung4

Trials

Showing 76 to 69 of 69. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.